Log In
BCIQ
Print this Print this
 

XEN701

  Manage Alerts
Collapse Summary General Information
Company Xenon Pharmaceuticals Inc.
DescriptionAntisense compound that targets hepcidin-hemojuvelin pathway
Molecular Target
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPreclinical
Standard IndicationAnemia
Indication DetailsTreat anemia of inflammation
Regulatory Designation
PartnerIonis Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/22/2010

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today